Jump to start of content

ABIM's call center wait times may be longer than usual Expand/Collapse the ABIM alert.

Due to high volume, ABIM call center wait times may be longer than usual. You may also contact us via email at request@abim.org. We apologize for any inconvenience this may cause.

Breadcrumb trail:

Hematology Approval Committees

Longitudinal Knowledge Assessment 

Expand All | Collapse All

Morie A. Gertz, MD, MACP, Chair

Dr. Gertz is the Roland Seidler, Jr. Professor of the Art of Medicine and Chair of the Department of Medicine, Mayo Clinic. He is board certified Internal Medicine, Hematology, and Medical Oncology, and is an active participant in the Maintenance of Certification program. Previously, Dr. Gertz served as the Treasurer for the International Myeloma Society and was the former President of Mayo Staff Officers and Councilors. He was the former Chair of the Mayo Personnel Committee. He currently serves on the American Society of Hematology Training Program Committee.

He has been recognized as the 2014 Jan Waldenstrom Medal for Medical and Scientfic Acheivements in Waldenström's Macroglobulinemia and is a Mayo Distinguished Clinician. He is recognized for contributions in amyloidosis and Waldenstrom's macroglobulinemia. He has authored over five hundred peer-reviewed publications in the field and is a frequently invited speaker nationally.

Dr. Gertz is a Master of the American College of Physicians. His undergraduate degree was awarded with highest distinction from Northwestern University graduating Phi Beta Kappa. Dr. Gertz received his medical degree cum laude from Loyola Medical School in Maywood, Illinois and was elected to Alpha Omega Alpha the medical honor society. He completed a 3-year medical residency at Rush Presbyterian St. Luke’s Hospital in Chicago, Illinois, and was voted Resident of the Year for two of those years.

As of July 2021, Dr. Gertz reported the following external relationships:

Funding for clinical trial expenses and staff, from the following companies:

  • Alnylam, for a trial of imRNA for familial amyloidosis, providing funding for staff, paid to Mayo Clinic.
  • Ionis, for a trial of IRNA for familial amyloidosis, providing funding for staff and expenses.
  • Protega Pharma, for a trial of serum TTR, paid to Mayo Clinic.
  • Pfizer, for a trial of tafamidis for cardiac amyloidosis, providing funding for staff, paid to Mayo Clinic.

Attendance at investigators’ meetings, with compensation as listed from the following company:

  • Akcea Therapeutics, to discuss a strategic planning model, receiving reimbursement for travel expenses and honoraria.

Service on data and safety monitoring boards for the following company, with honoraria:

  • Celgene, for a Phase III trial of venetoclax.

Service on research-related expert panel or advisory board for the following company, with compensation as listed:

  • Celgene, to advise on medical content of lectures sponsored by the company, receiving reimbursement for travel expenses and honoraria.

Research-related consulting for the following company, with honoraria:

  • AbbVie

Industry-supported continuing medical education supported by the following, with compensation as listed:

  • Alnylam, receiving honoraria.

Teaching in industry-sponsored satellite symposia with funding from the following company, with compensation as listed:

  • Research to Practice, receiving reimbursement for travel expenses and honoraria.

Dr. Gertz serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Hematology, Training Committee, receiving reimbursement for travel expenses.
  • Amyloidosis Support Network, receiving reimbursement for travel and other expenses associated with providing lectures to patients.
  • International Waldenstroms Macroglobulinemia Foundation, receiving reimbursement for travel and other expenses associated with providing lectures to patients.

Charles Abrams, MD

Dr. Abrams is an active hematologist and specializes in the care of patients with hemostatic/thrombotic disorders or other diseases related to non-malignant hematology. His laboratory, which has been funded by the National Institute of Health for over 25 years, is focused on understanding thrombosis, megakaryopoiesis, and hematopoiesis.

Dr. Abrams is the Director and Founder of the University of Pennsylvania/Children's Hospital of Philadelphia Blood Center for Patient Care & Discovery, as well as the Vice Chair for Research and Chief Scientific Officer of the Department of Medicine at the University of Pennsylvania School of Medicine. He is currently a member of the Hematology Longitudinal Approval Committee at the American Board of Internal Medicine. He has previously served as the President of the American Society of Hematology and was on the Board of Directors at the American Board of Internal Medicine.

Dr. Abrams earned his medical degree from Yale University in New Haven, Connecticut. He completed his residency at the Hospital at the University of Pennsylvania and Temple University Hospital and his fellowship at the Hospital at the University of Pennsylvania.

As of July 2021, Dr. Abrams reported no ongoing external relationships:

Richard Larson, MD

Dr. Richard Larson is Professor of Medicine in the Section of Hematology/Oncology and Director of the Hematologic Malignancies Clinical Research Program at the University of Chicago. He was a Fellow of the Leukemia Society of America and was granted a Clinical Oncology Career Development Award from the American Cancer Society. He has been a member of the faculty in the Section of Hematology/Oncology and the Comprehensive Cancer Center at the University of Chicago since 1983.

He was Director of the Leukemia Clinical Research Program at the University of Chicago from 1983 to 2000, during which time he established the adult allogeneic bone marrow transplant program at the University of Chicago Medical Center in 1986. He is board certified in Internal Medicine, Hematology, and Medical Oncology, and has served as a member of the Hematology Subspecialty Board of the American Board of Internal Medicine.

Between 1997-2011, Dr. Larson was chair of the Leukemia Committee of the Cancer and Leukemia Group B (CALGB), where he directed a large portfolio of clinical trials and correlative laboratory studies in acute and chronic leukemias. He is currently a member of the National Cancer Institute's Leukemia Steering Committee and the American Board of Internal Medicine’s Hematology Longitudinal Approval Committee.

Dr. Larson is a former Councilor on the Executive Committee of the American Society of Hematology and served as the Treasurer of ASH between 2011-2014. He was awarded the Henry M. Stratton Medal for Clinical Science in 2019. He has been a faculty member at ASH's Clinical Research Training Institute, and he has been an invited speaker at the Highlights of ASH in North America, Latin America, Asia, and the Mediterranean.

He received his medical degree from the Stanford University School of Medicine in 1977, and completed his postdoctoral training in internal medicine, hematology, and medical oncology at the University of Chicago.

As of November 2021, Dr. Larson reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Chicago, from the following companies:

  • Novartis, for a Phase III clinical trial with asciminib in chronic myeloid leukemia, and for a Phase III clinical trial with nilotinib for leukemia.
  • Daiichi Sankyo, for a Phase III clinical trial with quizartinib for leukemia.
  • Astellas, for Phase I/II and III clinical trials with gilteritinib for leukemia.
  • Celgene, for a Phase III trial of AG221 in leukemia.
  • Rafael Pharmaceuticals, for a Phase III clinical trial in acute myeloid leukemia.
  • Cellectis, for a Phase I clinical trial in acute lymphoblastic leukemia.
  • Forty Seven, for a Phase I/II trial of magrolimab in myelodysplastic syndrome and acute myeloid leukemia.
  • Gilead, for a Phase III clinical trial of magrolimab in myelodysplastic syndrome.

Service on data and safety monitoring boards for the following companies, with honoraria:

  • Novartis, for a Phase III clinical trial of MBG453 in myelodysplastic syndrome.
  • Takeda, for a Phase III clinical trial of ponatinib in chronic myeloid leukemia.
  • Epizyme, for a Phase II trial of EZH2 inhibitor.
  • Actinium, external review committee member.

Service on a research-related expert panel or advisory board for the following companies, with honoraria:

  • Novartis, for study management committee for oversight of a phase III trial of nilotinib in leukemia.
  • CVS, for formulary review.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with honoraria:

  • Novartis, for consulting on asciminib.

Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:

  • Continuing medical education lectures on diagnosis and treatment of hematologic malignant diseases, funded by multiple companies.

Work as an author or editor for following companies, with compensation as listed:

  • UpToDate®, receiving compensation for authorship and editorial services.

Ming Lim, MD

Dr. Lim has been an Assistant Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah since October 2018. She currently serves as a member of the Hematology Longitudinal Knowledge Asessment Approval Committee at the American Board of Internal Medicine. She is the recipient of two foundation-sponsored grants to determine the epidemiology and risk factors for inhibitor development in non-severe hemophilia A patients. She has co-authored over 30 peer-reviewed publications.

She is board certified in both Hematology and Medical Oncology. Her clinical interest lies in the field of hemostasis and thrombosis. Her research interest is focused on complications affecting patients with congenital bleeding disorders, specifically hemophilia patients with inhibitors.

Dr. Lim earned her medical degree at Cambridge University, England and completed her two-year foundation training in the United Kingdom. She then completed residency in internal medicine at the Mayo Clinic Rochester and fellowship training in hematology and oncology at University of North Carolina at Chapel Hill.

As of July 2021, Dr. Lim reported the following external relationships:

Service on a research-related expert panel or advisory board for the following companies, with honoraria:

  • Sanofi
  • Argenx
  • Dova
  • Hema Biologics

Dr. Lim serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Hemostasis and Thrombosis Research Society, Board of Directors, Research Colloquium, Trainee Workshop Planning Committee, receiving honoraria.
  • American Society of Hematology, Subcommittee on Stewardship and Systems-Based Hematology, without compensation.
  • National Comprehensive Cancer Network, Cancer Associated VTE Panel, without compensation.

Dr. Lim is also a recipient of the Hemostasis and Thrombosis Research Society Mentored Research Award and receives grant funding from the Foundation for Women and Girls with Blood Disorders.

Michael Williams, MD

Dr. Williams joined the Department of Medicine faculty at the University of Virginia (UVA) Emily Couric Clinical Cancer Center, an NCI-designated Cancer Center. He has served in several leadership roles including Chief of the Hematology/Oncology Division. His patient care and research interests include mantle cell lymphoma, other non-Hodgkin lymphomas and CLL, with a focus on targeted agents and immuno-therapeutics. He serves the Scientific Advisory Board of the Lymphoma Research Foundation as an Emeritus member. He was honored by the inaugural LRF Mantle Cell Lymphoma Leadership Award in 2021 and by establishment of the Dr. Michael Williams Abstract Achievement Award for MCL Research.

He is a member of the Eastern Cooperative Oncology Group Lymphoma Core Committee and of the European Mantle Cell Lymphoma Network.  Dr. Williams is past Chair of the Hematology Subspecialty Board of the American Board of Internal Medicine (ABIM), a past member of the ABIM Council, and currently serves on the ABIM Hematology Longitudinal Knowledge Assessment Approval Committee. He serves on the editorial boards of the Journal of Clinical Oncology and Annals of Lymphoma, and is Associate Editor for Hematologic Malignancies for the New England Journal Medicine Group Journal Watch Oncology and Hematology. He participates regularly in national and international programs devoted to research and education in lymphoma and CLL.

Dr. Williams received his medical degree from the University of Cincinnati College of Medicine and master of science degree from the Harvard School of Public Health. He completed his medical residency, chief Residency and fellowship at UVA Health.

As of November 2021, Dr. Williams reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to the University of Virginia, from the following companies:

  • Allos, receiving funding for clinical trial expenses and staff.
  • Janssen, receiving funding for clinical trial expenses, salary support and staff.
  • Pharmacyclics, receiving funding for clinical trial expenses and staff.
  • TG Therapeutics, receiving funding for clinical trial expenses and staff.

Dr. Williams serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Lymphoma Research Foundation, Member of Scientific Advisory Board, Emeritus member as of June 2021, without compensation.

Traditional, 10-Year MOC Exam

Expand All | Collapse All

Robert T. Means Jr., MD, Chair

Robert T. Means Jr., MDDr. Means, a board certified internist and hematologist, was the former Dean and presently Professor of Internal Medicine at the James H. Quillen College of Medicine, East Tennessee State University in Johnson City, Tennessee.

Before coming to Quillen, he was Executive Dean of the University of Kentucky College of Medicine. Other positions Dr. Means held at Kentucky included Senior Associate Chair of Internal Medicine, Interim Director of the Markey Cancer Center and Chief of the Medical Service at the Lexington VA Medical Center. He served as Director of the Hematology Oncology Division at the Medical University of South Carolina and was on faculty at the University of Cincinnati and Vanderbilt.

Dr. Means is the Chair of the American Board of Internal Medicine Hematology Board Exam Committee. He is past President of the Southern Society for Clinical Investigation and a Fellow of the American College of Physicians. He is also an Associate Editor of the Journal of Investigative Medicine and serves on editorial boards for the American Journal of the Medical Sciences, Blood Research, and International Journal of Hematology. He is on the Medical & Scientific Advisory Board of the Iron Disorders Institute.

Dr. Means received his bachelor's degree in biochemistry from Rice University in Houston, Texas. He earned his medical degree at Vanderbilt University in Nashville, Tennessee. He trained in internal medicine at Baylor College of Medicine Affiliated Hospitals in Houston, Texas, before returning to Vanderbilt for a fellowship in hematology.

As of August 2021, Dr. Means reported the following external relationships:

Work as an author or editor for following companies, with compensation as listed:

  • Lippincott Williams Wilkins/Wolters Kluwer, receiving compensation as an editor for Wintrobe’s Clinical Hematology.
  • UpToDate®, receiving compensation as an author and editor.

Dr. Means serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Southern Society for Clinical Investigation, Member of Executive Advisory Committee, without compensation.
  • Iron Disorders Institute, Member of the Medical & Scientific Advisory Board, without compensation.

Kelly M. Davidson, MD

Kelly M. Davidson, MDDr. Davidson is an Assistant Professor of Medicine in the Division of Hematology and Oncology at the University of Virginia (UVA), where she practices hematology at the Emily Couric Clinical Cancer Center. She was initially certified in Internal Medicine, Medical Oncology and Hematology, and maintains her certification in Hematology.

Dr. Davidson specializes in a variety of benign and malignant hematologic diseases, with a focus on cellular hematology. She sees patients with myeloproliferative and myelodysplastic disorders, red cell disorders including sickle cell disease, bone marrow failure syndromes, plasma cell dyscrasias, mast cell disorders and disorders of hemostasis and thrombosis. In addition to clinical practice, Dr. Davidson teaches in the second-year medical student course in hematology and plays an active role in resident and fellowship training at UVA. She previously practiced both hematology and oncology at Associates in Oncology/Hematology in Rockville, Maryland.

From 2015 through present, Dr. Davidson has been named to the list of Best Doctors in America. In 2016, she served on the American Board of Internal Medicine (ABIM) Standard Setting Panel for the Hematology Maintenance of Certification Exam, and currently serves as a member of the ABIM Hematology Board Exam Committee. She has been a member of the American Society of Hematology since 2003.

Dr. Davidson received a biology degree summa cum laude from Georgetown University and her medical degree from Washington University in St. Louis. She completed internship and residency in internal medicine at Beth Israel Deaconess Medical Center in Boston and fellowship training in hematology and oncology at UVA.

As of April 20222 Dr. Davidson reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Virginia, from the following company:

  • Takeda

Service on a research-related advisory board for the following companies, with honoraria:

  • Blueprint Medicines 
  • Sanofi

Chancellor E. Donald, MD

Chancellor E. Donald, MDDr. Donald currently practices at Lourdes Oncology Associates in Lafayette, Louisiana. In 2010, he joined the practice and became Managing Partner in 2014. Additionally, at Our Lady of Lourdes Regional Medical Center, he functions as Medical Director of the oncology service line, a member of the Medical Executive Committee and as a Trustee on the Board of Directors.

Dr. Donald is board certified in Internal Medicine, Hematology and Medical Oncology. He serves on the American Board of Internal Medicine’s Hematology Exam Board Committee.

Dr. Donald advocates for patients with malignancies and hematologic disorders. He is currently President of the Louisiana Oncology Society. He has been appointed to the Board of Directors of the Community Oncology Alliance. In 2013, he was given the Spirit of Hope Award by the American Cancer Society. The American Society of Hematology (ASH) selected him for its Committee on Practice. He also holds the position of ASH’s alternate delegate to the American Medical Association’s House of Delegates. Since 2012, he has served as the Hematology Representative for Louisiana for the Medicare Carrier Advisory Committee (CAC). He served as co-Chair of the 2017 Annual CAC meeting at the American Society of Clinical Oncology headquarters and was again selected for that role for the 2018 annual meeting at the ASH headquarters. For the 2017 Annual Meeting of ASH, he served as the clinical designee to the Program Committee.

Dr. Donald graduated magna cum laude from Florida A&M University and received his medical degree from the University of Miami School of Medicine. He completed his internship, residency and fellowship at Tulane University. He served as Chief Resident and Chief Fellow there and currently holds the position of Clinical Assistant Professor within Tulane’s Department of Hematology/Oncology.

As of June 2022, Dr. Donald reported the following external relationships:

Service on a research-related expert panel or advisory board for the following company, receiving honoraria:

  • Curio Sciences, for serving on an advisory board discussing therapeutics treatment strategies of lung cancer.

Dr. Donald serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Hematology, Standing Member of Committee on Practice; Delegate to the House of Delegates of the American Medical Association; receiving reimbursement for travel expenses.
  • Community Oncology Alliance, Board of Directors, Member, without compensation.
  • Taking Aim at Cancer in Louisiana Initiative, Chief Medical Officer, without compensation.
  • Louisiana Oncology Society, Immediate Past President, without compensation.

Elizabeth Hexner, MD

Elizabeth Hexner, MDDr. Hexner is a physician scientist with an interest in education and two major research interests in malignant hematology: the first is in cellular therapies and hematopoietic stem cell transplantation, and the second is in myeloproliferative neoplasms (MPN). Both have a translational focus and align with her clinical roles as Medical Director of the Center for Cellular Immunotherapies and as Director of the University of Pennsylvania MPN program. In MPN she has designed and executed preclinical studies of janus kinase (JAK) inhibitors and also used bioassays and correlative studies in MPN patients treated with JAK inhibitors focused on resistance.

Her work in MPN, cellular therapies, stem cell transplantation, primary cell systems and preclinical and clinical investigation allows me to intersect productively with basic science, transfusion medicine, regulatory, and clinical colleagues. In another major area of focus. Dr. Hexner serves as the Associate Director of the National Institutes of Health Clinical and Translational Science Awards-funded Masters in Translational Research program at the University of Pennsylvania, serving on the education, selection, and curriculum committees and overseeing a cohort of candidates as a programmatic mentor.

Dr. Hexner received her medical degree from Columbia University. She completed her residency at New York Presbyterian/Columbia University Medical Center and her fellowship at the Hospital of the University of Pennsylvania.

As of August 2022, Dr. Hexner reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to the University of Pennsylvania, from the following companies:

  • Blueprint Medicines, receiving funding for staff and expenses.
  • TMUNITY, receiving funding for salary support.

Service on data and safety monitoring boards for the following companies, with compensation for travel expenses and honoraria:

  • Blueprint Medicines

Research-related advisory boards for the following companies, with compensation for travel expenses and honoraria:

  • Pharmessentia
  • AbbVie  

Cindy Leissinger, MD

Dr. Leissinger is Professor of Medicine and Clinical Professor of Pediatrics and Pathology at Tulane University in New Orleans, Louisiana, and is Chief of the Hematology/Oncology Division. She became Director of the Louisiana Comprehensive Hemophilia Care Center (now the Louisiana Center for Bleeding and Clotting Disorders) in 1992, and has remained in that position ever since. She is board certified in Internal Medicine and Hematology.

In addition to caring for patients with bleeding and clotting disorders, Dr. Leissinger oversees an active research program. She participates in several clinical research groups, and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management.

Dr. Leissinger is a member of the American Board of Internal Medicine Hematology Board Exam Committee. Additionally, she is actively involved in the American Society of Hematology, the International Society on Thrombosis and Hemostasis, and the Hemostasis and Thrombosis Research Society.

Dr. Leissinger received her medical degree from Tulane University School of Medicine. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at the National Institutes of Health in Bethesda, Maryland, and a clinical fellowship in hematology and medical oncology at Tulane.

As of October 2021, Dr. Leissinger reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to Tulane University, from the following companies:

  • Biomarin, for a study of a FVIII gene therapy.
  • Roche, for a study of a new Factor VIII mimetic protein.

Service on a research-related expert panel or advisory boards for the following companies, with honoraria:

  • Takeda, on bleeding disorders, mainly hemophilia and Von Willebrand disease.
  • Bayer, on bleeding disorders, mainly hemophilia and Von Willebrand disease.
  • CSL Behring, on bleeding disorders, mainly hemophilia and Von Willebrand disease.
  • Roche, on bleeding disorders, mainly hemophilia and Von Willebrand disease.
  • Chiesi, on sickle cell disease.
  • Sanofi, on bleeding disorders.
  • Catalyst, on hemophilia.
  • Dova, on immune thrombocytopenia.
  • Forma, on sickle cell disease.
  • Global Blood Therapeutics, on sickle cell disease.
  • Uniqure, on hemophilia gene therapy.

Industry-supported continuing medical education supported by the following, with honoraria:

  • Genentech, regarding pharmacovigilance
  • Catalyst, regarding hemophilia care

Laura C. Michaelis, MD

Laura C. Michaelis, MDDr. Michaelis is an Associate Professor of Medicine at the Medical College of Wisconsin. She is the Associate Vice Chair of the Department of Medicine and serves as the Director of Inpatient Services for the Division of Hematology/Oncology. She is board certified in Hematology and her professional interests include clinical research in acute and chronic leukemias.

Previously, Dr. Michaelis was the Director of the Fellowship Program at Loyola University Medical Center, where she worked as a general hematologist for seven years after finishing her fellowship. While practicing at Loyola, Dr. Michaelis became interested in physician-patient education and advocacy as well as peer-to-peer education. She co-chaired the Chicago MPN roundtable, an organization devoted to teaching patients and practitioners about the standard of care in this rare condition.

Dr. Michaelis is active in the American Society of Hematology (ASH), where she serves on the publications committee and communications committee and is the Editor-in-Chief of The Hematologist. She also serves on the Educational Committee for the Society of Hematologic Oncology and also serves on the American Board of Internal Medicine Hematology Board Exam Committee. She is a member of the ASH guidelines committee on leukemia in the elderly and continues to participate actively in patient-education forums, speaking nationally on myeloproliferative disorders to patient groups.

Dr. Michaelis did her fellowship in hematology and oncology at the University of Chicago and completed her internship and residency in internal medicine at the Brigham and Women’s Hospital in Boston. She graduated from Harvard Medical School in 2000. Before entering medical school, Dr. Michaelis was a newspaper and magazine reporter. She earned a Master of Journalism degree from Northwestern University and worked at news outlets throughout the country, including the MacNeill-Lehrer NewsHour, the Los Angeles Times and Congressional Quarterly.

As of June 2022, Dr. Michaelis reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to Medical College of Wisconsin, from the following company:

  • Jazz

Service on data and safety monitoring boards for the following companies, without compensation:

  • Jazz

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:

  • Celgene, for serving on an advisory board, receiving honoraria.
  • Novartis, for serving on an advisory board, receiving honoraria.
  • Incyte, for serving as an expert witness, receiving a stipend.

Work as an author or editor for following company, with compensation as listed:

  • American Society of Hematology, Editor-in-Chief for The Hematologist, receiving honoraria and reimbursement for travel expenses. She also receives compensation for authorship.

Dr. Michaelis serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Society of Hematology, speaker at national meeting, receiving reimbursement for travel expenses and honoraria.
  • Society for Hematologic Oncology, speaker at national meeting, receiving reimbursement for travel expenses and honoraria.